FR2898503A1 - Cosmetic or dermatological composition with a slimming effect comprises a substance that stimulates expression of SIRT1 protein deacetylase - Google Patents
Cosmetic or dermatological composition with a slimming effect comprises a substance that stimulates expression of SIRT1 protein deacetylase Download PDFInfo
- Publication number
- FR2898503A1 FR2898503A1 FR0650849A FR0650849A FR2898503A1 FR 2898503 A1 FR2898503 A1 FR 2898503A1 FR 0650849 A FR0650849 A FR 0650849A FR 0650849 A FR0650849 A FR 0650849A FR 2898503 A1 FR2898503 A1 FR 2898503A1
- Authority
- FR
- France
- Prior art keywords
- expression
- sirt
- cosmetic
- stimulating
- increasing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 239000002537 cosmetic Substances 0.000 title claims abstract description 12
- 230000000694 effects Effects 0.000 title claims abstract description 11
- 102000000344 Sirtuin 1 Human genes 0.000 title abstract 2
- 108010041191 Sirtuin 1 Proteins 0.000 title abstract 2
- 241000196324 Embryophyta Species 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 17
- 230000004936 stimulating effect Effects 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 210000000577 adipose tissue Anatomy 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 8
- 241000219317 Amaranthaceae Species 0.000 claims description 7
- 208000035484 Cellulite Diseases 0.000 claims description 7
- 241000209445 Nelumbonaceae Species 0.000 claims description 7
- 206010049752 Peau d'orange Diseases 0.000 claims description 7
- 230000036232 cellulite Effects 0.000 claims description 7
- 241000234646 Cyperaceae Species 0.000 claims description 6
- 241000209477 Nymphaeaceae Species 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 2
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 claims 1
- 101000890626 Homo sapiens Allograft inflammatory factor 1 Proteins 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 description 14
- 230000011759 adipose tissue development Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 4
- 229960000830 captopril Drugs 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000201841 Celosia Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 235000008954 quail grass Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- DHFUFHYLYSCIJY-WSGIOKLISA-N CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DHFUFHYLYSCIJY-WSGIOKLISA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 241000209490 Nymphaea Species 0.000 description 1
- 235000016791 Nymphaea odorata subsp odorata Nutrition 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
Abstract
Description
UTILISATION DE SUBSTANCES AGISSANT SUR LES SIRT- 1 POUR LEUR ACTIVITEUSE OF SUBSTANCES ACTING ON SIRT-1 FOR THEIR ACTIVITY
AMINCISSANTESLIMMING
La présente invention concerne l'utilisation cosmétique de substances agissant sur les protéines déacétylases SIRT-1 pour leur activité amincissante. L'invention se rapporte également aux compositions amincissantes comprenant au moins une substance agissant sur les protéines déacétylases SIRT-1. The present invention relates to the cosmetic use of substances acting on the SIRT-1 deacetylase proteins for their slimming activity. The invention also relates to slimming compositions comprising at least one substance acting on the SIRT-1 deacetylase proteins.
De nos jours, le culte de la minceur modèle un certain idéal de silhouette et on se soucie de plus en plus de son image et de son aspect extérieur. En particulier, beaucoup de femmes cherchent à lutter contre la cellulite qui donne à la peau un aspect granuleux et capitonné dit en peau d'orange et une consistance molle et flasque. Nowadays, the cult of slimming models a certain ideal of silhouette and we care more and more about its image and its external appearance. In particular, many women seek to combat cellulite which gives the skin a grainy and padded appearance said in orange peel and a soft and flabby consistency.
C'est pourquoi l'objectif de la présente invention est de proposer des produits présentant une action amincissante capables de lutter efficacement contre la cellulite et de limiter les désagréments qui en découlent. La cellulite correspond à un développement excessif de la masse grasse dans la couche profonde de la peau, le tissu adipeux, généralement au niveau des hanches et des cuisses. Le tissu adipeux est composé de cellules spécialisées : les adipocytes. Ces cellules proviennent de cellules précurseurs, les préadipocytes, et sont présentes à différents stades de différenciation au niveau du tissu adipeux. Le processus de différenciation adipocytaire, l'adipogenèse, est sous la dépendance de la communication cellulaire qui se fait par l'intermédiaire d'hormones et de facteurs de croissance. Plusieurs facteurs de transcription participent également au déroulement du programme de différenciation, notamment les PPAR (Peroxysome Proliferator-Activated Receptors) qui sont induits de façon précoce. Une fois arrivés à maturation, les adipocytes sont des cellules arrondies contenant des lipides sous forme de gouttelettes constituées presque exclusivement de triglycérides. Le tissu adipeux remplit plusieurs fonctions essentielles : protection mécanique et thermique, production de différentes substances endocrines et paracrines et surtout stockage ou mise à disposition de l'énergie. C'est cette dernière fonction qui est impliquée dans la cellulite, faisant de l'adipocyte une cellule extensible, qui augmente ou diminue de volume sous l'effet du remplissage des graisses, appelé lipogenèse, ou de la vidange, la lipolyse. Plusieurs phénomènes sont impliqués dans le dépôt de graisses au niveau du tissu adipeux : - un déséquilibre entre la lipogenèse et la lipolyse, conduisant à une hypertrophie des adipocytes, et - une augmentation de l'adipogenèse, conduisant à une hyperplasie des adipocytes et donc à une augmentation du tissu adipeux. Aussi, pour répondre à son objectif, la présente invention vise à utiliser des substances capables d'agir sur ces mécanismes impliqués dans les désordres du tissu adipeux et dans la formation de la cellulite. En particulier, la présente invention se propose d'utiliser des substances capables de stimuler et/ou d'augmenter l'expression des protéines déacétylases SIRT-1 pour la préparation d'une composition destinée à une activité amincissante. This is why the objective of the present invention is to provide products having a slimming action capable of effectively fighting against cellulite and to limit the inconvenience resulting therefrom. Cellulite is an excessive development of fat mass in the deep layer of the skin, adipose tissue, usually at the hips and thighs. Adipose tissue is composed of specialized cells: adipocytes. These cells come from precursor cells, the preadipocytes, and are present at different stages of differentiation in adipose tissue. The process of adipocyte differentiation, adipogenesis, is dependent on cellular communication through hormones and growth factors. Several transcription factors also participate in the development of the differentiation program, including PPARs (Peroxysome Proliferator-Activated Receptors) that are induced early. Once mature, the adipocytes are rounded cells containing lipids in the form of droplets consisting almost exclusively of triglycerides. The adipose tissue fulfills several essential functions: mechanical and thermal protection, production of various endocrine and paracrine substances and especially storage or provision of energy. It is this latter function that is involved in cellulite, making the adipocyte an expandable cell, which increases or decreases in volume under the effect of fat filling, called lipogenesis, or emptying, lipolysis. Several phenomena are involved in the deposition of fat in the adipose tissue: - an imbalance between lipogenesis and lipolysis, leading to hypertrophy of the adipocytes, and - an increase in adipogenesis, leading to a hyperplasia of the adipocytes and therefore to an increase in adipose tissue. Also, to meet its purpose, the present invention aims to use substances capable of acting on these mechanisms involved in adipose tissue disorders and in the formation of cellulite. In particular, the present invention proposes to use substances capable of stimulating and / or increasing the expression of the SIRT-1 deacetylase proteins for the preparation of a composition intended for a slimming activity.
Les SIRT-1 sont des enzymes NAb(+)-dépendantes (Nicotinamide Adénine binucélotide - dépendantes) qui jouent un rôle à la fois : - au niveau de la mobilisation des graisses dans les adipocytes, et au niveau de l'adipogenèse. SIRT - 1 are NAb (+) - dependent (Nicotinamide adenine binucelotide - dependent) enzymes that play a role at the same time: - at the level of fat mobilization in adipocytes, and at the level of adipogenesis.
En effet, les SIRT-1 sont capables d'intervenir au niveau de la lipolyse et de moduler l'accumulation des triglycérides dans les adipocytes matures. Ainsi, l'utilisation de substances capables de stimuler et/ou d'augmenter l'expression des SIRT-1 selon la présente invention permet de réduire la quantité de triglycérides accumulés dans les adipocytes matures et de diminuer le volume des cellules graisseuses. En parallèle, les SIRT-1 sont capables de relier et de réprimer les gènes contrôlant le régulateur de graisse PPAR-y (Peroxysome Proliferator-Activated Receptors gamma), facteur de transcription participant à l'adipogenèse. Indeed, SIRT-1 are able to intervene at the level of lipolysis and modulate the accumulation of triglycerides in mature adipocytes. Thus, the use of substances capable of stimulating and / or increasing the expression of SIRT-1 according to the present invention makes it possible to reduce the amount of triglycerides accumulated in mature adipocytes and to reduce the volume of fat cells. In parallel, SIRT-1 are able to bind and repress the genes controlling the PPAR-y (Peroxysome Proliferator-Activated Receptors gamma) fat regulator, a transcription factor involved in adipogenesis.
De fait, l'utilisation de substances capables de stimuler et/ou d'augmenter l'expression des SIRT-1 selon la présente invention permet également de moduler l'activité du facteur de transcription PPAR-y et de limiter l'adipogenèse. Ainsi, le nombre d'adipocytes matures dans le tissu adipeux diminue. L'utilisation d'au moins une substance capable de stimuler et/ou d'augmenter l'expression des SIRT-1 selon l'invention, permet donc de réduire à la fois le nombre et le volume des cellules graisseuses du tissu adipeux et de limiter la cellulite. De manière préférentielle les substances capables de stimuler et/ou d'augmenter l'expression des SIRT-1 selon la présente invention sont des actifs 20 obtenus à partir de végétaux. En particulier, ces végétaux peuvent être choisis par exemple parmi les familles des Amaranthacées, des Cyperacées, des Nymphaeacées et des Nelumbonacées. Les substances capables de stimuler et/ou d'augmenter l'expression des SIRT-1 selon l'invention sont destinées à être incorporées au sein de compositions 25 cosmétiques et/ou dermopharmaceutiques. La composition selon l'invention peut contenir de 0,01 à 20 % d'au moins une substance capable de stimuler et/ou d'augmenter l'expression des SIRT-1. In fact, the use of substances capable of stimulating and / or increasing the expression of SIRT-1 according to the present invention also makes it possible to modulate the activity of the PPAR-γ transcription factor and to limit adipogenesis. Thus, the number of mature adipocytes in adipose tissue decreases. The use of at least one substance capable of stimulating and / or increasing the expression of the SIRT-1s according to the invention thus makes it possible to reduce both the number and the volume of fat cells of the adipose tissue and of limit cellulite. Preferably, the substances capable of stimulating and / or increasing the expression of SIRT-1 according to the present invention are active agents obtained from plants. In particular, these plants may be chosen for example from the families Amaranthaceae, Cyperaceae, Nymphaeaceae and Nelumbonaceae. Substances capable of stimulating and / or increasing the expression of SIRT-1 according to the invention are intended to be incorporated into cosmetic and / or dermopharmaceutical compositions. The composition according to the invention may contain from 0.01 to 20% of at least one substance capable of stimulating and / or increasing the expression of SIRT-1.
L'administration d'une composition contenant au moins une substance capable de stimuler et/ou d'augmenter l'expression des SIRT-1 selon l'invention est de préférence effectuée par voie topique. La composition selon l'invention peut se présenter sous forme de crèmes, émulsions huile-dans-eau, eau-dans-huile ou émulsions multiples, solutions, suspensions ou encore poudres. La présente invention est maintenant décrite en s'appuyant sur des résultats de tests effectués à partir d'exemples non limitatifs de substances capables de stimuler et/ou d'augmenter l'expression des SIRT-1. 1 EVALUATION DE L'EFFET DE SUBSTANCES SELON L'INVENTION 1.1 Test 1 : Evaluation in vitro de l'expression des ARNm codant pour les SIRT-1 L'objectif de cette étude est d'évaluer la capacité de principes actifs à augmenter l'expression des ARNm codant pour les SIRT-1. Administration of a composition containing at least one substance capable of stimulating and / or increasing the expression of SIRT-1 according to the invention is preferably carried out topically. The composition according to the invention may be in the form of creams, oil-in-water emulsions, water-in-oil or multiple emulsions, solutions, suspensions or powders. The present invention is now described based on test results made from non-limiting examples of substances capable of stimulating and / or increasing the expression of SIRT-1. 1 EVALUATION OF THE EFFECT OF SUBSTANCES ACCORDING TO THE INVENTION 1.1 Test 1: In vitro Evaluation of the Expression of the mRNA Encoding the SIRT-1 The objective of this study is to evaluate the capacity of active ingredients to increase the expression of mRNAs encoding SIRT-1.
Cette étude consiste à placer des préadipocytes dans un milieu permettant leur différenciation en adipocytes matures, auquel on ajoute dans quatre tests les principes actifs suivants : - un principe actif issu de Célosia, une plante de la famille des Amaranthacées, à 0,1% et à 0,25%, - un principe actif issu de Souchet, une plante de la famille des Cyperacées, à 0,5%, et - un principe actif issu de Nénuphar, une plante de la famille des Nymphaeacées, à 0,1%. On prépare également en parallèle un échantillon témoin positif en présence de 25 captopril à 1mM. L'expression des ARNm de SIRT-1 est réalisée par PCR (Polymerase Chain Reaction) quantitative. This study consists of placing preadipocytes in a medium allowing their differentiation into mature adipocytes, to which the following active ingredients are added in four tests: - an active ingredient derived from Celosia, a plant of the Amaranthaceae family, at 0.1% and at 0.25%, - an active principle derived from Souchet, a plant of the family Cyperaceae, at 0.5%, and - an active ingredient from Nénuphar, a plant of the family Nymphaeacées, at 0.1% . A positive control sample was also prepared in the presence of captopril at 1 mM. The expression of the SIRT-1 mRNAs is carried out by quantitative PCR (Polymerase Chain Reaction).
Les résultats sont exprimés dans le tableau suivant : Taux d'expression des ARNm de SIRT-1 (en /G) Témoin 100 Captopril 1mM 114 Principe actif issu de Célosia, plante de la 103 famille des Amaranthacées, 0,1% Principe actif issu de Célosia, plante de la 125 famille des Amaranthacées, 0,25% Principe actif issu de Souchet, plante de 114 la famille des Cyperacées, 0,5% Principe actif issu de Nénuphar, plante 164 de la famille des Nymphaeacées, 0,1% On constate que les principes actifs issus de plantes des familles Amaranthacées, Cyperacées et Nymphaeacées augmentent l'expression des ARNm codant pour les SIRT-1. The results are expressed in the following table: Expression level of SIRT-1 mRNA (in / G) Control 100 Captopril 1mM 114 Active ingredient from Celosia, plant of the family 103 Amaranthaceae, 0.1% Active ingredient from of Celosia, plant of the 125 family of Amaranthaceae, 0.25% active ingredient from Souchet, plant of 114 family Cyperaceae, 0.5% active ingredient from water lily, plant 164 of the family of Nymphaeaceae, 0.1 It is found that the active ingredients derived from plants of Amaranthaceae, Cyperaceae and Nymphaeaceae families increase the expression of the mRNAs coding for SIRT-1.
1.2 Test 2 : Evaluation in vitro de la synthèse des SIRT-1 Cette étude a pour but de déterminer l'effet de principes actifs sur la synthèse des SIRT-1. Le protocole opératoire consiste à traiter des adipocytes avec un principe actif issu de Lotus, une plante de la famille des Nelumbonacées, à 0,1% et à 0,5%. 1.2 Test 2: In vitro evaluation of SIRT-1 synthesis This study aims to determine the effect of active ingredients on the synthesis of SIRT-1. The operative protocol consists of treating adipocytes with an active principle derived from Lotus, a plant of the family Nelumbonaceae, at 0.1% and 0.5%.
On prépare également en parallèle un échantillon témoin positif en présence de captopril à 1mM. On dose les protéines totales et on détermine l'évolution du taux de SIRT-1 par Western Blot. A positive control sample in the presence of captopril at 1mM is also prepared in parallel. The total proteins are assayed and the evolution of the SIRT-1 level is determined by Western blotting.
Les résultats sont présentés ci-dessous : Taux de SIRT-1 (en /G) Témoin 100 Captopril 1mM 113 Principe actif issu de Lotus, plante de 119 la famille des Nelumbonacées 0,1% Principe actif issu de Lotus, plante de 126 la famille des Nelumbonacées 0,5% Ces résultats montrent qu'un principe actif issu de plantes de la famille des Nelumbonacées à 0,1% et à 0,5% favorise la synthèse des SIRT-1. The results are presented below: SIRT-1 (in / G) rate Control 100 Captopril 1mM 113 Active ingredient from Lotus, plant of the family Nelumbonaceae 0.1% Active ingredient from Lotus, plant of 126 family 0.5% of Nelumbonaceae These results show that an active ingredient from plants of the Nelumbonaceae family at 0.1% and 0.5% promotes the synthesis of SIRT-1.
2 EXEMPLES DE COMPOSITIONS La présente invention couvre aussi les compositions cosmétiques et/ou dermopharmaceutiques incluant au moins une substance capable d'agir sur les SIRT-1 selon la présente invention dans différentes formes galéniques, adaptées à l'administration par voie topique cutanée. Ces compositions peuvent se présenter notamment sous forme de crèmes, émulsions huile-dans-eau, émulsions eau-dans-huile, émulsions multiples, solutions, suspensions ou poudres. Elles peuvent être plus ou moins fluides et avoir l'aspect d'une crème, d'une lotion, d'un lait, d'un sérum, d'une pommade, d'un gel, d'une pâte ou d'une mousse, ou sous forme solide. Ces compositions contiennent entre 0,01 et 20% en poids de substance(s) capable(s) d'agir sur les SIRT-1 selon la présente invention. Les exemples de compositions qui suivent sont obtenus par mélange des différents composants. Les quantités indiquées sont données en pourcentage de poids. 2.1 Exemple de gel crème amincissant : La formulation est la suivante : - Cetearyl octonoate : 10,0% - Ethanol : 8,0% - Principe actif agissant sur SIRT-1 : 4,0% - Arachidyl alcool/Behenyl Alcool/ Arachidyl glucoside : 2,0% - Polyacrilamide/C13C14 paraffine/ Laureth7 : 2,0% - Myreth-3 Myristate : 1,0% - Glycerol : 3,0% -bimethicone : 1,0% - Phenonip : 0,7% - Eau : 68,3% 2.2 Exemple de gel amincissant : La formulation est la suivante : - Cetearyl octonoate : 2, 0% - Ethanol : 8,0% - Principe actif agissant sur SIRT-1 : 5,0% biméthicone : 5,0% - Isononyl isononanoate : 3,0% - C13-14 Isoparaffin/Isostearyl isostearate/sodium polyacrylate/ polyacrylamide/polysorbate 60 : 3,0% -Glycerol : 2,0% - Phenonip : 0,5% Eau : 71,5% EXAMPLES OF COMPOSITIONS The present invention also covers cosmetic and / or dermopharmaceutical compositions including at least one substance capable of acting on the SIRT-1s according to the present invention in different galenic forms, adapted for topical administration to the skin. These compositions may especially be in the form of creams, oil-in-water emulsions, water-in-oil emulsions, multiple emulsions, solutions, suspensions or powders. They can be more or less fluid and have the appearance of a cream, a lotion, a milk, a serum, an ointment, a gel, a paste or a foam, or in solid form. These compositions contain between 0.01% and 20% by weight of substance (s) capable of acting on the SIRT-1s according to the present invention. The following examples of compositions are obtained by mixing the various components. The quantities indicated are given as a percentage of weight. 2.1 Example of slimming cream gel: The formulation is the following: - Cetearyl octonoate: 10.0% - Ethanol: 8.0% - Active ingredient acting on SIRT-1: 4.0% - Arachidyl alcohol / Behenyl Alcohol / Arachidyl glucoside : 2.0% - Polyacrilamide / C13C14 paraffin / Laureth7: 2.0% - Myreth-3 Myristate: 1.0% - Glycerol: 3.0% -bimethicone: 1.0% - Phenonip: 0.7% - Water : 68.3% 2.2 Example of slimming gel: The formulation is as follows: Cetearyl octonoate: 2.0% Ethanol: 8.0% Active ingredient acting on SIRT-1: 5.0% bimethicone: 5.0 % - Isononyl isononanoate: 3.0% - C13-14 Isoparaffin / Isostearyl isostearate / sodium polyacrylate / polyacrylamide / polysorbate 60: 3.0% -Glycerol: 2.0% - Phenonip: 0.5% Water: 71.5%
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0650849A FR2898503B1 (en) | 2006-03-14 | 2006-03-14 | USE OF SUBSTANCES ACTING ON SIRT-1 FOR THEIR SMOOTHING ACTIVITY |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0650849A FR2898503B1 (en) | 2006-03-14 | 2006-03-14 | USE OF SUBSTANCES ACTING ON SIRT-1 FOR THEIR SMOOTHING ACTIVITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2898503A1 true FR2898503A1 (en) | 2007-09-21 |
| FR2898503B1 FR2898503B1 (en) | 2008-08-29 |
Family
ID=37075164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0650849A Expired - Fee Related FR2898503B1 (en) | 2006-03-14 | 2006-03-14 | USE OF SUBSTANCES ACTING ON SIRT-1 FOR THEIR SMOOTHING ACTIVITY |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2898503B1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1106551A (en) * | 1964-03-18 | 1968-03-20 | Roland Nessim Benhaim | Pharmaceutically-active extracts of the nympheaceae |
| JPH10330242A (en) * | 1997-05-29 | 1998-12-15 | Mikimoto Pharmaceut Co Ltd | Medicine for cosmetic and pharmaceutical cosmetic |
| US5925348A (en) * | 1996-02-23 | 1999-07-20 | Medical Doctor's Research Institute, Inc. | Methods utilizing compositions containing sacred lotus (methyltransferase) to treat aging skin |
| FR2775595A1 (en) * | 1998-03-09 | 1999-09-10 | Seppic Sa | Cosmetic compositions containing a synergistic combination of a lipoaminoacid and a plant extract of the family nympheaceae |
| FR2804319A1 (en) * | 2000-01-28 | 2001-08-03 | Clarins Lab | SLIMMING COSMETIC COMPOSITION COMPRISING AS AN ACTIVE AGENT A PLANT EXTRACT CONTAINING ANP |
| DE10219684A1 (en) * | 2001-05-04 | 2002-11-14 | Unternehmensberatung Reichenau | Health-promoting product, e.g. useful for treating intestinal disorders, comprises a fermented plant-based composition and probiotic bacteria |
| FR2862533A1 (en) * | 2003-11-21 | 2005-05-27 | Oreal | Topically applied slimming agent, useful e.g. for combating cellulite or orange-peel skin, containing activator of cellular interleukin 11 production, preferably hydroxy-stilbene derivative |
-
2006
- 2006-03-14 FR FR0650849A patent/FR2898503B1/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1106551A (en) * | 1964-03-18 | 1968-03-20 | Roland Nessim Benhaim | Pharmaceutically-active extracts of the nympheaceae |
| US5925348A (en) * | 1996-02-23 | 1999-07-20 | Medical Doctor's Research Institute, Inc. | Methods utilizing compositions containing sacred lotus (methyltransferase) to treat aging skin |
| JPH10330242A (en) * | 1997-05-29 | 1998-12-15 | Mikimoto Pharmaceut Co Ltd | Medicine for cosmetic and pharmaceutical cosmetic |
| FR2775595A1 (en) * | 1998-03-09 | 1999-09-10 | Seppic Sa | Cosmetic compositions containing a synergistic combination of a lipoaminoacid and a plant extract of the family nympheaceae |
| FR2804319A1 (en) * | 2000-01-28 | 2001-08-03 | Clarins Lab | SLIMMING COSMETIC COMPOSITION COMPRISING AS AN ACTIVE AGENT A PLANT EXTRACT CONTAINING ANP |
| DE10219684A1 (en) * | 2001-05-04 | 2002-11-14 | Unternehmensberatung Reichenau | Health-promoting product, e.g. useful for treating intestinal disorders, comprises a fermented plant-based composition and probiotic bacteria |
| FR2862533A1 (en) * | 2003-11-21 | 2005-05-27 | Oreal | Topically applied slimming agent, useful e.g. for combating cellulite or orange-peel skin, containing activator of cellular interleukin 11 production, preferably hydroxy-stilbene derivative |
Non-Patent Citations (2)
| Title |
|---|
| DATABASE WPI Week 199909, Derwent World Patents Index; AN 1999-100978, XP002405873 * |
| PICARD FREDERIC ET AL: "Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma", NATURE (LONDON), vol. 429, no. 6993, 17 June 2004 (2004-06-17), pages 771 - 776, XP002403487, ISSN: 0028-0836 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2898503B1 (en) | 2008-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004108063A2 (en) | Cosmetic use of sophorolipids as subcutaneous adipose cushion regulating agents and slimming application | |
| US20100233298A1 (en) | Cosmetic use of phytosphingosine as slimming agent and cosmetic compositions comprising phytosphingosine | |
| EP1019016B1 (en) | Active synergetic complex and cosmetic and/or pharmaceutical product containing this complex | |
| KR101698922B1 (en) | Composition for promoting hair growth and restoration | |
| JP2008239493A (en) | External preparation for skin | |
| FR2865652A1 (en) | USE OF PLANT EXTRACTS AND PURIFIED MOLECULES FOR LIPOLYTICALLY SLIMMING, COSMETIC, NUTRACEUTICAL OR PHARMACEUTICAL COMPOSITIONS. | |
| EP1399113B1 (en) | Cosmetic or dermatological composition comprising n-acylaminoamide derivatives | |
| JP4124648B2 (en) | Anti-liposis topical treatment composition based on garlic bulb extract and cosmetic and therapeutic use | |
| ITRM20130657A1 (en) | TREATMENT OF DERMATOPATHIES BY VEGETAL EXTRACT BY DAPHNE LAUREOLA | |
| FR2898503A1 (en) | Cosmetic or dermatological composition with a slimming effect comprises a substance that stimulates expression of SIRT1 protein deacetylase | |
| EP3758726A1 (en) | Tetraselmis extract | |
| EP1450834B9 (en) | Allium sativum bulb absolutes and therapeutic or cosmetic uses | |
| WO2005023234A1 (en) | Molecules exhibiting anti-adipogenic activity on adipocyte human cells | |
| EP1768684A1 (en) | Composition comprising a blue lotus extract having a relaxing effect on the skin | |
| EP4151203B1 (en) | Rapeseed meal extract, method for preparing same and use in cosmetics, in particular as a pro-pigmenting, slimming agent | |
| FR2849595A1 (en) | Use of cosmetic composition containing extract of Bocoa prouacensis for slimming the face and body, inhibits glycerol-3-phosphate dehydrogenase, an essential enzyme in lipogenesis | |
| FR2819409A1 (en) | Cosmetic or dermatological skin care compositions, especially for slimming the thighs and hips, treating cellulite and firming the skin, containing diosgenin as glyceryl-3-phosphate dehydrogenase inhibitor | |
| FR2871382A1 (en) | Topical cosmetic/dermatological composition, useful to fight against the signs of aging, comprises a complex extract of blue lotus and poppy | |
| JP2023184345A (en) | Fibroblast growth factor-5 (fgf-5) production promoter, and method for evaluating material that inhibits fgf-5 production | |
| FR2820978A1 (en) | NEW SLIMMING COSMETIC COMPOSITIONS CONTAINING BOLDINE | |
| WO2001032137A1 (en) | Slimming composition containing a substance inducing il-6 production | |
| KR20180041046A (en) | Composition comprising Linallol or as active ingredients for preventing hair loss or stimulating hair growth | |
| FR2871381A1 (en) | Topical cosmetic/dermatological composition, useful e.g. to fight against signs of cutaneous ageing, comprises an marsh mallow extract (Althea officinalis) | |
| FR2996127A1 (en) | Use of (2S)-2-aminopentanoic acid in a composition e.g. hair care composition, preferably shampoo, hair setting lotion and styling cream or gel for treating seborrhea of skin and scalp and for slowing down hair loss | |
| FR2968988A1 (en) | Use of Fabiana imbricata essential oil as soothing agent, and for preventing and/or treating skin reactions providing discomfort of the skin and/or scalp such as redness, itching, sensations of heat and/or burn, tightness and gnawing pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 11 |
|
| PLFP | Fee payment |
Year of fee payment: 12 |
|
| PLFP | Fee payment |
Year of fee payment: 13 |
|
| PLFP | Fee payment |
Year of fee payment: 15 |
|
| PLFP | Fee payment |
Year of fee payment: 16 |
|
| PLFP | Fee payment |
Year of fee payment: 17 |
|
| ST | Notification of lapse |
Effective date: 20231105 |